{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-304456","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.273055+00:00","generated_at":"2026-06-21T04:51:41.526157+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update","bullets":["Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.","Also discussed updates on the company's oncology pipeline programs.","Full presentation furnished as Exhibit 99.1; no specific numerical results disclosed in the filing text."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-304456","json":"https://secwatch.observer/filing/0001193125-22-304456.json","markdown":"https://secwatch.observer/filing/0001193125-22-304456.md","text":"https://secwatch.observer/filing/0001193125-22-304456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/0001193125-22-304456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/d313389d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:51:41.526157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}